Recall Z-2237-2020

Beckman Coulter Inc. · initiated April 30, 2019

Class II Terminated

Class II – products that might cause a temporary health problem or pose a slight threat of a serious nature

Product

Beckman Coulter Access Immunoassay Systems, Access Free T4 Thyroxine, REF 33880 (UDI:15099590225834) for use with Access Family of Immunoassay Systems including: Access 2, UniCel DxI 600, UniCel DxI 800, UniCel DxC 600i, UniCel DxC 660i, UniCel DxC 680i, UniCel DxC 860i, and UniCel DxC 880i systems.

Codes / lots: Catalog Number: 33880; all lots.

Reason for recall

The recalling firm characterized the potential interference effects of biotin (up to 1,200 ng/mL) on all biotin-mediated Access assays. The following six assays: Free T3-REF A13422, Total T3-REF 33830, Free T4-REF 33880, GI Mon-387687, Tg-REF 33860, and TgAbII-REF A32898 displayed significant interference (defined as a result bias greater than +/-10%) at 1,200 ng/mL of biotin.

FDA-determined cause: Other

Action taken

On 04/30/2019, an Urgent Medical Device Letter was sent via mail to affected consignees. Customers were instructed to access the updated Instructions for Use (IFU) Limitations and Interferences sections for the six affected Access immunoassays on the firm's website. Additionally they ask customers to do the following: 1) Share the information with laboratory staff and retain the notification as part of their laboratory Quality System documentation. If any of the affected product(s) have been forwarded to another laboratory, they are to provide them with a copy of the Urgent Medical Device Recall letter. 2) Respond within 10 days either electronically (if received communication via email) or manually (complete and return an enclosed Response Form). If there are any questions regarding the notice, contact the Customer Support Center: website: http://www.beckmancoulter.com By phone: call 1-800-854-3633 in the United States and Canada. Outside the United States and Canada, contact the local firm representative.

Details

Recall number
Z-2237-2020
Initiated
April 30, 2019
Posted by FDA
June 2, 2020
Terminated
December 28, 2021
Product code
CEC – Radioimmunoassay, Free Thyroxine
Quantity
1,322,438 units
Distribution
US Distribution: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusett, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico New York, North Carolina, North Dakota, Ohio, Oklahoma…
Recalling firm
Beckman Coulter Inc., Brea, CA

Official FDA recall record

Other products in the same recall event

RecallProductInitiated
Z-2238-2020 Class IIBeckman Coulter Access Immunoassay Systems, Access Free T3 Triiodothyronine, REF A13422…The recalling firm characterized the potential interference effects of biotin (up to 1,200 ng/mL) on all… 04/30/2019Terminated
Z-2239-2020 Class IIBeckman Coulter ACCESS Immunoassay Systems, Access Total T3 Triiodothyronine , REF 33830…The recalling firm characterized the potential interference effects of biotin (up to 1,200 ng/mL) on all… 04/30/2019Terminated
Z-2240-2020 Class IIBeckman Coulter ACCESS Immunoassay Systems, Access Thyroglobulin, REF 33860 (UDI:…The recalling firm characterized the potential interference effects of biotin (up to 1,200 ng/mL) on all… 04/30/2019Terminated
Z-2241-2020 Class IIBeckman Coulter ACCESS Immunoassay Systems, Access GI Monitor Cancer Antigen 19-9, REF…The recalling firm characterized the potential interference effects of biotin (up to 1,200 ng/mL) on all… 04/30/2019Terminated
Z-2242-2020 Class IIBeckman Coulter ACCESS Immunoassay Systems, Access Thyroglobulin Antibody II, REF A32898…The recalling firm characterized the potential interference effects of biotin (up to 1,200 ng/mL) on all… 04/30/2019Terminated